We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

204 hedge funds and large institutions have $3.33B invested in Xenon Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 86 increasing their positions, 51 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

142% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 19

69% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 51

59% more capital invested

Capital invested by funds: $2.1B → $3.33B (+$1.23B)

56% more funds holding in top 10

Funds holding in top 10: 9 → 14 (+5)

13% more funds holding

Funds holding: 180 → 204 (+24)

2.19% more ownership

Funds ownership: 95.63% → 97.83% (+2.2%)

4% less call options, than puts

Call options by funds: $39M | Put options by funds: $40.6M

Holders
204
Holders Change
+24
Holders Change %
+13.33%
% of All Funds
2.97%
Holding in Top 10
14
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+55.56%
% of All Funds
0.2%
New
46
Increased
86
Reduced
51
Closed
19
Calls
$39M
Puts
$40.6M
Net Calls
-$1.6M
Net Calls Change
+$6.69M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$86M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$49.6M
3
BlackRock
BlackRock
New York
+$38M
4
FLAM
First Light Asset Management
Minnesota
+$36.9M
5
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$31.5M

Top Sellers

1
BI
BVF Inc
California
-$33.1M
2
NIP
Nicholas Investment Partners
California
-$27.1M
3
Marshall Wace
Marshall Wace
United Kingdom
-$22.1M
4
SC
Samlyn Capital
New York
-$18.7M
5
B
Braidwell
Connecticut
-$16.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
CA
201
Crewe Advisors
Utah
$185 +$141 +4 New
JWA
202
JFS Wealth Advisors
Pennsylvania
$93 -$177 -5 -71%
DPW
203
DiNuzzo Private Wealth
Pennsylvania
$93 +$71 +2 New
AF
204
Advisornet Financial
Minnesota
$92 -$35 -1 -33%
RG
205
Redmile Group
California
– -$14.3M -419,568 Closed
EAM
206
Eventide Asset Management
Massachusetts
– -$14.1M -413,906 Closed
Holocene Advisors
207
Holocene Advisors
New York
– -$6.1M -178,470 Closed
GTC
208
Ghost Tree Capital
New York
– -$3.38M -98,951 Closed
MWM
209
Moran Wealth Management
Florida
– -$2.37M -69,510 Closed
Qube Research & Technologies (QRT)
210
Qube Research & Technologies (QRT)
United Kingdom
– -$1.85M -54,285 Closed
SFM
211
Sphera Funds Management
Israel
– -$1.33M -38,959 Closed
AR
212
Advisory Research
Illinois
– -$1.31M -38,326 Closed
JGC
213
J. Goldman & Co
New York
– -$628K -17,775 Closed
CM
214
Caption Management
Oklahoma
– -$336K -9,500 Closed
DTL
215
Dynamic Technology Lab
Singapore
– -$320K -9,371 Closed
Group One Trading
216
Group One Trading
Illinois
– -$283K -8,005 Closed
Walleye Trading
217
Walleye Trading
New York
– -$236K -6,923 Closed
ETC
218
Exchange Traded Concepts
Oklahoma
– -$136K -3,967 Closed
Belvedere Trading
219
Belvedere Trading
Illinois
– -$32.6K -955 Closed
PPC
220
Park Place Capital
Alabama
– -$752 -22 Closed
LFG
221
Larson Financial Group
Missouri
– -$581 -17 Closed
LC
222
Lindbrook Capital
California
– -$478 -14 Closed
HCP
223
Hexagon Capital Partners
Arkansas
– -$342 -10 Closed
5 6 7 8
9

XENE Hedge Fund Activity: Q4 2023 in Review

204 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2023, worth a combined $3.33B — up 59% from $2.1B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new XENE positions and 19 closed out — a net gain of 27 holders — while 86 added to existing stakes and 51 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $86M. The largest seller was BVF Inc, cutting an estimated $33.1M.

  • 204 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2023, up from 180 in Q3 2023.
  • Funds reported $3.33B of Xenon Pharmaceuticals stock for Q4 2023, up 59% quarter-over-quarter.
  • 46 funds opened new Xenon Pharmaceuticals positions in Q4 2023 and 19 closed out, a net change of +27 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2023 was Wellington Management Group, an estimated $86M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2023 was BVF Inc, an estimated $33.1M sold.

Based on aggregated 13F filings for Q4 2023.